BLRX News and Press, BioLineRx Ltd. From 09/19/23

BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer PR Newswire Abstracts to be Published on American Association of Cancer Researc...

2023-09-18 12:55:34 ET The Allure and Risks of Penny Stock Trading in 2023 Penny stocks represent an exciting yet risky path to profits for active investors. Defined as stocks priced under $5 per share, these cheap equities boast the potential for astronomical returns on minimal investm...

2023-09-18 01:28:37 ET Summary BioLineRx has received approval for their stem cell mobilizing compound, motixafortide, for certain forms of blood cancer. The compound has shown impressive results in mobilizing stem cells in patients, with a high success rate in optimal stem cell c...

2023-09-12 08:42:44 ET Losers: Acelyrin ( SLRN ) -56% announces top-line results from placebo-controlled clinical trial of Izokibep for moderate-to-severe Hidradenitis Suppurativa. Sight Sciences ( SGHT ) -31% on updated guidance . Super League Gaming (...

2023-09-11 07:47:12 ET More on biolinerx Seeking Alpha’s Quant Rating on biolinerx Historical earnings data for biolinerx Financial information for biolinerx BioLineRx Ltd. ( BLRX ) Q2 2023 Earnings Call Transcript BioLineRx: PDUFA Catalyst...

BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma PR Newswire - APHEXDA is the first i...

2023-09-08 10:00:08 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...

2023-09-07 08:43:42 ET Losers: NeuBase Therapeutics ( NBSE ) -25% . Sportsman's Warehouse Holdings ( SPWH ) -23% after Q2 earning release . Palisade Bio ( PALI ) -19% . Yext ( YEXT ) -16% after Q2 earning release . Verint Systems...

BioLineRx Ltd. (NASDAQ: BLRX) is one of today's top gainers. The company's shares are currently up 20.38% on the day to $2.43. BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3...

2023-08-30 12:58:05 ET BioLineRx Ltd. (BLRX) Q2 2023 Earnings Conference Call August 30, 2023 7:30 PM ET Company Participants John Lacey - Head of Investor Relations and Corporate Communications Phil Serlin - Chief Executive Officer Mali Zeevi - Chief Financial O...